Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...

NCT02484404 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

268

Enrollment

NIH

Sponsor class

Conditions

Colorectal Neoplasms
Breast Neoplasms

Interventions

DRUG: Olaparib
DRUG: Cediranib
DRUG: Durvalumab

Sponsor

National Cancer Institute (NCI)